-
-
-
-
-
-
-
Takeda reports positive phase 3 results for zasocitinib psoriasis drug
-
-
-
-
-
-
-
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Withou
-
-
-
-
-
-
-
Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection (Refractory, With or Without Resistance
-
-
71,790 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

